To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris

NCT00050661 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

6

Enrollment

OTHER

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: Daclizumab
DEVICE: NB-UVB

Sponsor

Rockefeller University

Collaborators

[object Object]